Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Accumulated Expenses (2023 - 2025)

Onconetix (ONCO) has disclosed Accumulated Expenses for 2 consecutive years, with $255679.0 as the latest value for Q3 2024.

  • On a quarterly basis, Accumulated Expenses rose 62.97% to $255679.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $255679.0, a 62.97% increase, with the full-year FY2023 number at $50000.0, changed N/A from a year prior.
  • Accumulated Expenses was $255679.0 for Q3 2024 at Onconetix, up from $100000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.9 million in Q1 2024 to a low of $50000.0 in Q4 2023.